## Index

```
abuse-of-discretion standard, 13, 18, 23, 26, 27, 28, 443 n.18
additive effect, 429
anecdotal evidence, 90-92
association (between exposure and disease), 336, 337, 348, 357, 419-26
Bayesian approach (Bayes' theorem), 117, 132-33, 151-52, 466, 467, 536-44
case reports, 474, 475
causal effect of injury
    disputes over, 289-91
    using evidence from clinical practice for, 91 n.19
causal inferences, 256-60
causality, 184-85
causation, 323
    external causation, 451 n.45, 452, 457, 468-78, 479
    proof by expert testimony, 32-38
confidence interval, 117-19, 243-44, 354-55, 360-61
confidentiality, 52-53
    ethical obligation of survey research organization, 272
    professional standards for survey researchers, 272
    protecting identities of individual respondents, 271-72
    surveyor-respondent privilege, not recognized, 272
confounders (third variables), 138
confounding factors, 369-73, 423, 428
correlation, 204-05
correlation coefficients, 135-39
damages
    antitrust damages, 322-25
         causation, 323
         exclusionary conduct, 324
         lost profits, 322
         scope, 322-23
         "tying" arrangement, 324-25
    apportionment, 309-10, 320, 321
    avoided cost, 293-94
    causal effect of injury, disputes over, 289-91
    characterization of harmful event, 284-94
         "but-for" analysis, 284-87
         and costs, 293-94
         disputes over economic effects, 287-89
    compensation
         stock options, 294
         tax treatment of, 291-93
    damages study, 280-81, 328-29
    disaggregation, see multiple challenged acts
    double-counting, avoiding, 286, 312, 316, 320, 322
    earnings, what constitutes, 295
    employment law, 310
    expectation, 283
    expert's qualifications, 282-83
    explanatory variables, 323
    future earnings, projection of, 299-300
         actual earnings of plaintiff after harmful event, 299
         profitability of business, 299
```

```
damages, continued
    future losses, discounting, 300-05
         appraisal approach, 305
         capitalization factor, 303-04
         interest rate, 301-03
         offset by growth in earnings, 302
    future losses, projection of, 300
    in general, 280-81
    intellectual property damages
         apportionment of, 320-22
         in general, 316-22
         market-share analysis (sales), 318-19
         price erosion, 319-20 "reasonable royalty" and designing around the paternt, 316-17, 321
    liquidated damages, 326-27
    lost profit, 320
    measuring losses, tax considerations, 291-93
    mitigation, 295-96, 312-14
    multiple challenged acts, 305-07
    patent infringement by public utility, 309-10
    personal lost earnings, 311-16
         benefits, 311-12
         discounting, 315
         mitigation, 312-14
         projected earnings, 311, 314
         retirement and mortality, 316
    prejudgment interest, calculation of, 297-98
    price erosion, 287, 288, 319-20
    and regression analysis, 282
    reliance, 283
    securities damages, 325-26
         market effect of adverse information, 326
         turnover patterns in ownership, 326
    structured settlements, 311
    subsequent unexpected events, 311
    and surveys, 282
Daubert, 442-43, 489, 537, 546, 551, 553
    as viewed by a scientist, 81-82
    gatekeeping function, 489
    see generally 10-38
defendant's fallacy, 539
dependent variable, choosing, 181, 186-87, 195
DNA evidence
    affinal model, 530
    allele, 492, 496
    amplification, 497-98, 515
    autoradiograph, 517
    band shift, 517
    basic product rule, 525-31, 556
    chip, 552
    database, 532-34
    Daubert, 489, 537, 546, 551, 553
         gatekeeping function, 489
```

```
DNA evidence, continued
    defendant's fallacy, 539
    degradation, 506, 507, 514, 516
    deoxyribonucleic acid (DNA)
        applications of non-human DNA technology, 549-59
        definition, 487, 491-96
        and Federal Rules of Evidence
             Rule 104, 523 n.175
             Rule 401, 523 n.175
             Rule 403, 500 n.69, 517 n.145, 523 n.175, 537, 544, 545
             Rule 702, 500 n.69, 537, 544, 545
        laboratory analysis of,
             Bayes' theorem, 536, 544
             binning, 535
             match, 516-19, 534
                 window, 535
    microchondrial DNA, 495
        sequence, 492
    equilibrium
        Hardy-Weinberg, 526, 528, 557, 558
        linkage, 526, 528, 557
    genome, 491
    genotype, 493, 494, 502, 508, 518, 519, 520
    multilocus, 525
    single locus, 526
    heterozygote, 508
    homozygote, 508
    interim ceiling method, 528
    likelihood ratio
        admissibility, 543-45
        definition, 534-36
    locus, 492
    mitochondria, 495, 505
    nucleotide, 491
    nucleus, 491, 505
    proficiency test, 511-12
    prosecutor's fallacy, 539, 539 n.239
    quality assurance, 509-12
    quality control, 509-12
    random amplified polymorphic DNA (RAPD), 552, 554
    random match probability, 525
        admissibility, 530, 537-48
        and databases, 532, 533
        juror comprehension of, 537-45
    random mating, 525
    reverse dot blot, 517
    sequence-specific oligonucleotide (SSO) probe, 561
    short tandem repeat (STR), 494
    single nucleotide polymorphism (SNP), 492
    Southern blotting, 501
    testing methods
        PCR, 488, 493 n.32, 497, 500, 504, 506, 507, 515, 551, 552, 561
        restriction fragment length polymorphism (RFLP), 501, 506, 556
        variable number tandem repeat (VNTR), 494, 500-03
```

```
DNA evidence, continued
    transposition fallacy, 544
    true match, 534
    typing
         amplified fragment length polymorphism (AFLP), 499 n.63, 552
         base pair (bp), 491, 492, 505
         chromosome, 491
         polymorphism, 494, 496
dose-response relationship, 346, 347, 377, 406, 475
ecological fallacy, 344
engineering
    compared with science, 579-88
         difference, 579
             struggles to define in the courts, 579-80
         similarities, 584-86
             artistic component, 586
    design
         assumptions, 592-94, 596, 605
         computer-aided design (CAD), 594
         conservatism
              generally, 596
              difficulty of defining, 600-01, 602
         constraints, 592
         experience as pitfall, 599-600
         factor of safety, 596
         failure
              as guide to succesful designs, 612
              role of, 604
              value of, 604, 608
         loads
              design loads, 592
              dead load, 593-94
         pushing the envelope, 597-99, 613
         state of the art, 595
    engineers
         distinguised from scientists, 581
         professional qualifications, 581-84
    history, 612-16
    in general, 578
epidemiology
    association (between exposure and disease), 336, 337, 348, 357
         measuring exposure
             biological marker, 366
    ecological fallacy, 344
    etiology, 335
    false results (erroneous association)
    alpha, 356, 357
    beta, 362
    biases, 349, 354, 355, 363-69
         information bias, 365-68
              misclassification bias, 368
         selection bias, 363-65
```

```
epidemiology, continued
    false results, continued
         confounding factor, 369-73
             controlling for
                  stratification, 373
                  multivariate analysis, 373
         false negative error, 362
         false positive error, 356-61
         power, 362-63
         random (sampling) error, 354
              confidence interval, 354-55, 360-61
             statistical significance, 354, 357, 359-60, 362
         true association, 355
    general causation, 336, 374-79, 382
         agent, 335, 336, 337, 338-39, 340
             single, 379
             multiple, 379
         biological plausibility, 375, 378
         dose-response relationship, 346, 347, 377
         guidelines for determining, 375-79
         replication, 377-78
    in general, 335-38
    incidence, 343, 348
    prevalence, 343
    specific (individual) causation, 336, 381-86
         admissibility of evidence, 382
         sufficiency of evidence, 382-86
    specificity, 379
    studies
         animal (in vivo), 345-46
         extrapolation, 346
         generalizability of, 372 n.305
         human (in vitro), 346-47
         in general, 337, 338-47
         clinical, 338, 339
         experimental, 338-39
         multiple, 380-81
              meta-analysis, 380
         observational, 339-45
             case-control, 342-43
                  and bias, 363-64, 365-66
              cohort, 340-42
                  and bias, 364
                  and toxicology, compared, 346-47
             cross-sectional, 339, 343-44
              ecological, 340, 344-45
              hospital-based, 364
              time-line (secular trend), 345
              toxicologic, 345-47
         research design, 338-39, 372
```

```
epidemiology, continued
    study results, interpretation of
         adjustment for non-comparable groups, 352-54
         attributable risk, 351-52, 385
         odds ratio, 350-51
         relative risk, 348-49, 376-77
         standardized mortality ratio (SMR), 353
error in measuring variables, 200
etiology, 335, 451, 458, 460, 474, 476, 477 n.139
expert, qualification of, 201, 282-83
    advanced degree, 415-16
    basis of toxicologist's expert opinion, 416
    board certification, 417, 448
    other indicia of expertise, 418
    physician, 416, 447
    professional organization, membership in, 417
expert evidence, management of, see management of expert evidence
expertise
    in engineering, 581-84
    in statistics, 87
    in surveys, 238
explanatory variables, 92 n.23, 181, 187-89, 195-98, 323
exposure (to toxic substance), 472-73
extrapolation, 346
    from animal and cell research to humans, 410-11, 412, 419
    in statistical experiments, 96-97
falsification (falsifiability), 70-71, 78
Federal Rules of Evidence
    Rule 102, 29
    Rule 104, 523 n.175
    Rule 104(a), 11
    Rule 202, 27
    Rule 401, 523 n.175
    Rule 403, 86, 500 n.69, 517 n.145, 523 n.175, 537, 544, 545
    Rule 702, 11, 12, 15, 18, 21, 22, 86, 443 n.18, 500 n.69, 537, 544, 545
forensic identification (challenges to), 31-32
Frye test, 11, 23, 24, 25, 26
gatekeeping function, 11, 15, 16, 17, 18, 19, 23, 27, 30, 38, 489
general acceptance, 11, 23, 24, 25, 26
general causation, 336, 374-79, 382, 419-22
General Electric Co. v. Joiner, 10, 13-15, 18, 26, 32-34
generalizability of studies, 372 n.305
how science works
    historical background, 68-69
    myths (and countermanding facts)
         duty of falsification, 78
         honesty and integrity of scientists, 79
         open-mindedness of scientists, 78
         pseudo-science easily distinguisted, 78
         science as open book, 78
         theories only theories, 79
         triumph of reason over authority, 77-78
```

```
how science works, continued
    professional scientists
         institutions for, 75–76
         reward system and, 76-77
         rigor in reporting procedures and data, 73, 79
    science and law compared
         different word use, 80-81
         different objectives, 81
    science as adversary process, 74
    theoretical underpinnings
         falsification (falsifiability), 70-71, 78
              as element in Daubert, 79 n.15, 81 n.17
              as scientist's duty, 78
              difficulties with, 71
         paradigm shifts, 71-73
              shortcomings as theory, 73
         scientific method, 69-70
         testability
              as element in Daubert, 79 n.15
hypothesis tests, 121-30, 192, 356 n.60
"intellectual rigor" test, 18, 19, 23, 24, 25, 26
intercept, 140
Kumho Tire Co. v. Carmichael, 10, 15-23, 26-33, 35-38
least-squares regression, 217-18
likelihood ratio
    admissibility, 543-45
    definition, 534-36
linear association, 136-37
linear regression model, 207-10
management of expert evidence
    collateral estoppel, 48
    confidentiality, 52–53
    court-appointed experts, 43, 45, 52, 59-63
    discovery of
         attorney work product, 50
         testifying experts, 49
         nontestifying experts, 51
         nonretained experts, 51
         court-appointed experts, 52
    expert testimony
         need for, 47
         timing of designation of testifying experts, 43
         limiting the number of testifying experts, 47-48
    magistrate judges, use of, 48-49
    motions in limine, 53–54
    pretrial conferences
         defining and narrowing issues, 43
         experts reports, 44, 50-51
         initial conference, 42
         final pretrial conference, 56-57
    protective orders, 52–53
    reference guides, 45-47
    special masters, use of, 43, 63-66
```

```
management of expert evidence, continued
    summary judgement, 54-56
    technical advisor, 59
    trial
         defining the trial structure, 57
         jury management, 57-58
         structuring expert testimony, 58
         presentation of evidence, 58
    videotaped depositions, 52
measurement error, 145 n.213, 200, 518 n.148
medical testimony
    Americans with Disabilities Act, 441, 479
    Bayes' theorem, 466, 467
    Black v. Food Lion, Inc., 442 n.15, 445 n.29
    case reports, 474, 475
    case series, 474
    causation (external), 451 n.45, 452, 457, 468-78, 479
    Daubert, 442-43
    diagnostic tests
         clinical tests, 460-61
         generally, 457-58
         laboratory tests, 459-460
         pathology tests, 460
    differential diagnosis, 443-4, 463, 467, 470 n.112, 476 n.135, 477 n.139
    differential etiology, 443-4, 470 n.112, 474 n.126, 476 n.135, 477 n.139
    dose-response, 475
    ERISA, 441, 479, 478 n.145
    etiology, 451, 458, 460, 474, 476, 477 n.139
    exposure (to toxic substance), 472-3
     General Electric Co. v. Joiner, 442 n.14, 443 n.18
    Kumho Tire, 442-43
    sensitivity, 461, 465-66
    specificity, 461, 465-66
    symptomatology, 453-54
    tissue biopsy, 457, 458, 460
    true negative rate, see "specificity"
    true positive rate, see "sensitivity"
multiple regression analysis
    causality, 184-85
    census undercount cases, questionable use in, 183
    computer output of, 218-19
    correlation, 204-05
    death penalty cases, questionable use in, 183
         statistical studies of,
    dependent variable, choosing, 181, 186-87, 195
    employment discrimination, 181-83, 191
         scatterplot, 204
         use of statistics in assessing disparate impact of,
         and use of survey research, 233
    expert, qualification of, 201
    explanatory variables, 181, 187-89, 195-98
    feedback, 195-96
    forecasting, 219-221
         standard error of, 220-21
```

```
multiple regression analysis, continued
    growth of use in court, 182
    hypothesis tests, 192
    in general, 181-85, 204-21
    interpreting results, 191-200
         correlation versus causality, 183
         error in measuring variables, 200
         practical significance versus statistical significance, 191-95
         regression slope, 212
         robustness, 195-200
         stastical significance, 191-95
    linear regression model, 207-10
    measurement error, 200
    model specification (choosing a mocel), 186-91
         errors in model, 197-98
    nonlinear models, 210
    null hypothesis, 193-95, 214, 219
    patent infringement, 183
    precision of results, 212-18
         goodness-of-fit, 215-17
         least-squares regression, 217-18
         standard error, 212-15, 216, 221
    p-value, 194, 219
    regression line, 207, 208-10
         goodness-of-fit, 209, 215-16
         regression residuals, 210
    research design, 185-91
         formulating the question for investigation, 186
    spurious correlation, 184, 195
    standard deviation, 213
    statistical evidence, 201-03
    statistical significance
         hypothesis test, 194
         p-value, 194
null hypothesis, 122-23, 193-95, 214, 219, 356
observational studies, 94-96, 339-45
odds ratio, 109, 350-51
patient's medical history, 428-31
posterior probabilities, 131-33, 534, 536-37, 544-45
power, 125-26, 362-63
prosecutor's fallacy, 539, 539 n.239
p-values, 121-30, 156-57, 194, 219, 357
random (sampling) error, 115, 354
randomized controlled experiments, 93-94
reference guides, 45-47
regression analysis, 282
regression lines, 139-43, 207, 208-10
regression slope, 212
research design
    in vitro, 410
    in vivo, 406-09
scatter diagrams (scatter plot), 134-35, 204
```

```
science, how it works, see how science works
scientific method, 69-70
sensitivity, 461, 465-66
    multiple-chemical hypersensitivity, 416 n.43
slope, 140
    regression slope, 212
specific (individual) causation, 336, 381-86, 422-26
specificity, 379, 461, 465-66
standard deviation, 114, 213
standard error, 212-15, 216, 221
statistical significance, 191-95, 354, 357, 359-60, 362
    hypothesis test, 194
    p-value, 194
statistics
    anecdotal evidence, 90-92
    association
         income and education, 134
    average, in statistical parlance, 113 n.100
    Bayesian approach, 117, 132-33, 151-52
    confidence intervals, 117-19
    confounders (third variables), 138
    correlation coefficients, 135-39
    data, collection of
         censuses, 343
         individual measurements, 102-04
         observational studies, 94-96
         proper recording, 104
         randomized controlled experiments, 93-94
         reliability, 102-03
         surveys, 98-102
         validity, 103-04
    data, inferences drawn from
         estimation, 117-21
         in general, 115-17
         hypothesis tests, 121-30
         p-values, 121-30, 156-57
         posterior probabilities, 131-33
    data, presentation and analysis of
         center of distribution, 113-14
         graphs, 110-13
         interpreting rates or percentages, 107
         misleading data, 105-07
         percentages, 108
         variability, 114-15
    discrimination, 108, 145, 147-49
    enhancing statistical testimony, 88-89
         narrative testimony, 89
         sequential testimony, 89
    expertise in, 87
         applied statistics, 86
         probability theory, 86
         theoretical statistics, 86
         two-expert cases, 87
```

```
statistics, continued
    in general, 85-86
    graphs
         association, 134-35
         distribution of batch of numbers, 112
         histograms, 112
         scatter diagrams, 134-35
         trends, 110-11
    linear association, 136-37
    mean, 113-114
    median, 113-14
    mode, 113
    normal curve, 155-58
    null hypothesis, 122-23
    odds ratio, 109
    one-tailed and two-tailed tests, 126-27
    outliers, 137
    percentage-related statistics, 108
    power, 125-26
         calculation of, 157-58
    random error, 115
    range, 114
    regression lines, 139-43
         intercept, 140
         slope, 140
         unit of analysis, 141-42
         and voting rights cases, 142-43
    standard deviation, 114
    standard error, 117-19, 148, 153
    statistical significance, 93 n.28, 116, 121, 123-25
    surveys, 98-102
    transposition fallacy, 131 n.167
    trends, 110-11
    two-tailed tests, see one-tailed tests
survey research
    admissibility of, 233
    advantages of, 231-32
    attorney participation in survey, 237
    causal inferences, 256-60
    change of venue, 240, 243, 261
    comparing survey evidence to individual testimony, 235-36
    computer-assisted interview (CAI), 262-63
    computer-assisted telephone interviewing (CATI), 262
    confidentiality
         ethical obligation of survey research organization, 272
         professional standards for survey researchers, 272
         protecting identities of individual respondents, 271-72
         surveyor-respondent privilege, not recognized, 272
    consumer impressions, 256
    data entry, 268
    design of survey, 236-39
    disclosure of methodology and results, 269-70
    in general, 231–36
    in-person interviews, 260-261
```

```
survey research, continued
    internet surveys, 264
    interviewer surveys, 264-67
         objective administration of survey
             procedures to minimize error and biases, 267
             sponsorship disclosure, 266
         selecting and training interviewers, 264-65
    mail surveys, 263-64
    objectivity of, 237-38
    pilot-testing, 271
         pretest, 249, 271
    population definition and sampling, 239-48
         bias, 245-47
         cluster sampling, 243
         confidence interval, 243-44
         convenience sampling, 244
         mail intercept survey, 246-47
         nonresponse, 245-46
         probability sampling, 242-44
         random sampling, 242
         representativeness of sample, 245
         response rates, 245-46
         sampling frame (or universe), 240-42
         screening potential respondents, 247
         selecting the sample population, 242-44
         stratified sampling, 243
         target population, 240
    purpose of survey, 236-39
    questions, 248-49
         ambiguous reponses, use of probes to clarify, 253-54
         clarity of, 248-49
         consumer impressions, 256
         control group or question, 256-60
         filter questions to reduce guessing, 249-51
         open-ended versus closed-ended questions, 251-55
         order of questions, effect of, 254-55
         pretests, 248-49
         primacy effect, 255
         recency effect, 255
    relevence of survey, 236-37
    reporting, 270-71
    responses, grouping of, 268
    skip pattern, 262-63, 265
    survey expertise, 238
    telephone surveys, 261-63
    use of surveys in court, 233-35
surveys, 98-102, 282
    see also survey research
testability
    as element in Daubert, 79 n.15
```

```
toxicology
    acute toxicity testing, 406-07
    additive effect, 429
    antagonism, 429
    association (see general and specific causation in this entry)
    chemical structure of compound. 421
    confounding factors, 423, 428
    dose-response relationship, 406
    and epidemiology, 413-15
    expert qualifications
         advanced degree, 415-16
         basis of toxicologist's expert opinion, 416
         board certification, 417
         other indicia of expertise, 418
         physician, 416
         professional organization, membership in, 417
    extrapolation from animal and cell research to humans, 410-11, 412, 419
    in general, 403–19
    general causation, 419-22
         animal testing, extrapolation from, 419-20
         biological plausibility, 422
         chemical structure of compound, 421
         in general, 419
         in vitro tests of compound, 422
         organ specificity of chemical, 420-21
    genome, human, effect of understanding on torts, 421
    good laboratory practice, 411-12
    multiple-chemical hypersensitivity, 416 n.43
    one-hit theory (model), 407-08
    patient's medical history
         competing causes (confounding factors) of disease, 428-29
         different susceptibilities to compound, 430
         effect of multiple agents, 429
         evidence of interaction with other chemicals, 429
         in general, 427-31
         laboratory tests as indication of exposure to compound, 428
         when data contradict expert's opinion, 430-31
    potentiation, 429
    regulatory proceedings, 404
    research design
         in general, 405-10
         in vitro, 410
         in vivo, 406-09
         maximum tolerated dose, 408-09
         no observable effect level, 407
         no threshold model, 407-08
    safety and risk assessments, 411-13
    specific causation, 422-26
         absorption of compound into body, 425
         excretory route of compound, 425
         exposure, 424
         metabolism, 425
         no observable effect level, 426
         regulatory standards, 423-24
```

# Reference Manual on Scientific Evidence

structure activity relationships (SAR), 421 synergistic effect, 429 torts, 404 transposition fallacy, 131 n.167, 544 two-expert cases, 87 workings of science, *see* how science works

## The Federal Judicial Center

#### Board

The Chief Justice of the United States, *Chair*Judge Stanley Marcus, U.S. Court of Appeals for the Eleventh Circuit
Judge Pauline Newman, U.S. Court of Appeals for the Federal Circuit
Chief Judge Jean C. Hamilton, U.S. District Court for the Eastern District of Missouri
Senior Judge Robert J. Bryan, U.S. District Court for the Western District of Washington
Judge William H. Yohn, Jr., U.S. District Court for the Eastern District of Pennsylvania
Judge A. Thomas Small, U.S. Bankruptcy Court for the Eastern District of North Carolina
Magistrate Judge Virginia M. Morgan, U.S. District Court for the Eastern District of Michigan
Leonidas Ralph Mecham, Director of the Administrative Office of the U.S. Courts

### Director

Judge Fern M. Smith

### **Deputy Director**

Russell R. Wheeler

### About the Federal Judicial Center

The Federal Judicial Center is the research and education agency of the federal judicial system. It was established by Congress in 1967 (28 U.S.C. §§ 620–629), on the recommendation of the Judicial Conference of the United States.

By statute, the Chief Justice of the United States chairs the Center's Board, which also includes the director of the Administrative Office of the U.S. Courts and seven judges elected by the Judicial Conference.

The Director's Office is responsible for the Center's overall management and its relations with other organizations. Its Systems Innovation & Development Office provides technical support for Center education and research. Communications Policy & Design edits, produces, and distributes all Center print and electronic publications, operates the Federal Judicial Television Network, and through the Information Services Office maintains a specialized library collection of materials on judicial administration.

The Judicial Education Division develops and administers education programs and services for judges, career court attorneys, and federal defender office personnel. These include orientation seminars, continuing education programs, and special-focus workshops. The Interjudicial Affairs Office provides information about judicial improvement to judges and others of foreign countries, and identifies international legal developments of importance to personnel of the federal courts.

The Court Education Division develops and administers education and training programs and services for nonjudicial court personnel, such as those in clerks' offices and probation and pretrial services offices, and management training programs for court teams of judges and managers.

The Research Division undertakes empirical and exploratory research on federal judicial processes, court management, and sentencing and its consequences, often at the request of the Judicial Conference and its committees, the courts themselves, or other groups in the federal system. The Federal Judicial History Office develops programs relating to the history of the judicial branch and assists courts with their own judicial history programs.